DK1621208T3 - DNA-vaccination til behandling af sutoimmun sygdom - Google Patents

DNA-vaccination til behandling af sutoimmun sygdom

Info

Publication number
DK1621208T3
DK1621208T3 DK05015105.9T DK05015105T DK1621208T3 DK 1621208 T3 DK1621208 T3 DK 1621208T3 DK 05015105 T DK05015105 T DK 05015105T DK 1621208 T3 DK1621208 T3 DK 1621208T3
Authority
DK
Denmark
Prior art keywords
disease
sutoimmune
treat
dna vaccination
vaccination
Prior art date
Application number
DK05015105.9T
Other languages
English (en)
Inventor
Lawrence Stanford Steinman
Hideki Garren
Pedro Jose Ruiz
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK1621208T3 publication Critical patent/DK1621208T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05015105.9T 1999-03-12 2000-03-10 DNA-vaccination til behandling af sutoimmun sygdom DK1621208T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26759099A 1999-03-12 1999-03-12
EP00912207A EP1168923B1 (en) 1999-03-12 2000-03-10 Dna vaccination for treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
DK1621208T3 true DK1621208T3 (da) 2010-05-10

Family

ID=23019424

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00912207T DK1168923T3 (da) 1999-03-12 2000-03-10 DNA vaccination til behandling af autoimmune sygdomme
DK05015105.9T DK1621208T3 (da) 1999-03-12 2000-03-10 DNA-vaccination til behandling af sutoimmun sygdom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK00912207T DK1168923T3 (da) 1999-03-12 2000-03-10 DNA vaccination til behandling af autoimmune sygdomme

Country Status (9)

Country Link
EP (3) EP1621208B1 (da)
JP (1) JP2003508346A (da)
AT (2) ATE453404T1 (da)
CA (1) CA2363269C (da)
DE (2) DE60023673T2 (da)
DK (2) DK1168923T3 (da)
ES (2) ES2338890T3 (da)
PT (1) PT1621208E (da)
WO (1) WO2000053019A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322185A3 (en) * 2001-11-21 2011-08-10 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
WO2008066330A1 (en) 2006-11-30 2008-06-05 Medipost Co., Ltd. Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
CN100571786C (zh) * 2007-03-26 2009-12-23 中国农业大学 一种预防和/或治疗自身免疫疾病的疫苗
KR20100054711A (ko) 2008-11-14 2010-05-25 메디포스트(주) 간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
EP2670421B1 (en) 2011-02-02 2017-12-06 Medipost Co., Ltd. Use of icam-1 for prevention or treatment of neurological diseases
GB201112806D0 (en) * 2011-07-26 2011-09-07 Bauer Johann Use of epitopes inducing specific tolerance for the prevention of tissue rejection
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
US10898590B2 (en) 2015-09-21 2021-01-26 Kolon Life Science, Inc. Method for delivery of biological molecule to nervous tissue
WO2023086969A2 (en) * 2021-11-12 2023-05-19 Ichor Medical Systems Inc. Treatment methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891435A (en) 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
AU3225097A (en) * 1996-06-03 1998-01-05 Auragen, Inc. Immunotherapy for autoimmune disease

Also Published As

Publication number Publication date
EP1168923B1 (en) 2005-11-02
CA2363269A1 (en) 2000-09-14
WO2000053019A1 (en) 2000-09-14
ATE453404T1 (de) 2010-01-15
DE60023673T2 (de) 2006-07-20
ATE308244T1 (de) 2005-11-15
EP1621208B1 (en) 2009-12-30
ES2338890T3 (es) 2010-05-13
DE60043624D1 (de) 2010-02-11
EP1168923A1 (en) 2002-01-09
DE60023673D1 (de) 2005-12-08
EP1168923A4 (en) 2002-06-26
DK1168923T3 (da) 2006-03-20
PT1621208E (pt) 2010-04-07
EP2177228A1 (en) 2010-04-21
ES2251974T3 (es) 2006-05-16
CA2363269C (en) 2012-06-12
JP2003508346A (ja) 2003-03-04
EP1621208A1 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
DK1621208T3 (da) DNA-vaccination til behandling af sutoimmun sygdom
DE69737969D1 (de) Dns-impfung zur einleitung einer suppressiven t-zell-antwort
MXPA04000982A (es) Metodos para movilizar celulas progenitoras/madre.
FI932678A (fi) Pao alfavirus baserande dna expressionssystem
ATE405243T1 (de) Säuglingspflegevorrichtung
SG170001A1 (en) Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
AR026059A1 (es) Virus de plantas modificadas y metodos para su uso
DK2921500T3 (da) Genetisk modificerede, humane, naturlige dræbercellelinjer
IL92382A0 (en) Immunotherapy involving cd28 stimulation
IL148008A0 (en) Conditional immortalisation of cells
DE60229375D1 (de) Immunmodulations-vorrichtung zur verwendung in tieren
UA85371C2 (ru) Модифицированный вирус коровьей оспы ankara для вакцинации новорожденных
DK0879056T3 (da) Modulation af Th1/Th2-cytokinekspression med ribavirin i aktiverede T-lymfocytter
Adachi et al. Expressions of peroxisome proliferator‐activated receptors (PPAR s) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPAR α modulates expressions of chemokines and epidermal differentiation‐related molecules in keratinocytes
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK1276497T3 (da) Blanding af defibrotid og G-CSF og anvendelse heraf til aktivering af hæmatopoietiske progenitorceller
ES2060680T3 (es) Polimeros de poliacrilato que utilizan un retardador de urea sustituida.
DE60033397D1 (de) Methode zur steigerung der produktionsleistung in tieren
PT858345E (pt) Uso de muteinas de citocinas do tipo selvagem como imunogenios
ES2147747T3 (es) Celulas atrapadas y su utilizacion como medicamento.
DK1100515T3 (da) Ex vivo-behandling af allogene og xenogene T-celler med pg39-antagonister
전경희 et al. Effect of Asterina pectinifera Lectin on Cytokine Production
CN204469024U (zh) 能量发生器
WO2002062837A3 (en) Cells with enhanced pkr expression for increasing cytokine production
ES2080114T3 (es) Procedimiento para preparar un factor inhibidor de la metastasis.